BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles

CureVac is undergoing a decisive transformation, shifting from an independent mRNA pioneer to a fully integrated unit within BioNTech. With the pivotal steps in motion, the takeover is effectively moving toward completion. For shareholders, the key question is what the present terms mean for their stake.

BioNTech Wins a Clear Majority

The takeover was effectively settled through the exchange tender. By the close of the first acceptance window, 184,071,410 CureVac shares had been tendered, representing about 81.74% of the issued and outstanding capital. This level meets the minimum acceptance threshold, clearing the path for the subsequent reorganization.

Under the deal, BioNTech will deliver American Depositary Shares (ADS) to those holders who accepted. The exchange ratio is set at 0.05363 BioNTech-ADS per CureVac share. This ratio is anchored to the volume-weighted average price of BioNTech-ADS at $101.88 over the ten trading days ending November 25, 2025.

Shareholders who did not tender face specific consequences. They are expected to receive, in the later reorganization, shares that incur a Dutch dividend withholding tax of 15%. Once the process completes, they will operate in a market with markedly lower liquidity.

Last Chance for Hesitant Holders

A final window remains for investors who have yet to tender. The additional acceptance period runs until Thursday, December 18, 2025, at 12:01 p.m. Eastern Time.

Following the expiration of this period, BioNTech plans to initiate the Post-Offer Reorganization. CureVac shares will then be delisted from all national trading venues. In addition to delisting, transferability restrictions are expected to rise, effectively narrowing secondary trading channels for those still holding CureVac stock.

Overwhelming Support from the General Meeting

Should investors sell immediately? Or is it worth buying CureVac?

The deal’s backing is reinforced by a strong vote from CureVac’s owners. At the extraordinary general meeting held on November 25, 2025, the necessary approvals were secured with broad support.

Key outcomes included:
– 99.16% of votes cast favored all resolutions tied to the exchange offer
– 70.52% of registered share capital participated in the vote
– 99.95% approval for the downstream merger resolution

These margins underpin the legal framework for integrating CureVac into BioNTech, signaling broad shareholder consent rather than broad opposition.

Index Removal and Strategic Context

Market dynamics have already begun reflecting the transition. On December 4, 2025, CureVac was removed from the NASDAQ Biotechnology Index, signaling that, for index providers, CureVac is no longer a stand-alone listed entity as it moves toward full control by BioNTech.

Strategically, the deal reshapes Europe’s mRNA landscape. CureVac’s platforms—from mRNA development and lipid nanoparticles to oncology programs—are slated to be folded into BioNTech’s R&D pipeline. The agreement also follows a previously announced settlement with GSK over mRNA-patent matters, eliminating significant legal uncertainties among the involved parties.

Market Picture and Current Trading

Trading activity has reflected the certainty around the process, with the stock moving within a relatively tight range in recent weeks. Over a 12-month horizon, the shares are in positive territory. The current price sits roughly 11% below the 52-week high and trades below the 50-day moving average, but remains above the 200-day moving average.

In sum, the market posture aligns with an ongoing transition rather than new operating developments. As the late December deadline passes and the post-offer reorganization proceeds, the path to full integration with BioNTech appears largely set.